Accepted for/Published in: JMIR Research Protocols
Date Submitted: Aug 31, 2020
Open Peer Review Period: Nov 7, 2020 - Nov 17, 2020
Date Accepted: Jan 21, 2021
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Can Bovine Lactoferrin Prevent Neonatal Infections in Low Birth Weight Newborns in Pakistan?
ABSTRACT
Background:
Background:
Sepsis is a common and severe complication in premature neonates, particularly those born with low birth weights (LBW) (<2500 g). Neonatal sepsis is steadily emerging as a leading cause of neonatal mortality in Pakistan. Lactoferrin (LF) is a natural product with broad-spectrum antimicrobial and glycoprotein that is actively involved in innate immune host responses. Clinical trials have revealed its protective effect on sepsis, but the lactoferrin dosage, duration, and its role in the prevention of sepsis are still uncertain.
Objective:
Objective:
To establish the efficacy of bovine Lactoferrin (BLF) in the prevention of late-onset sepsis and to determine an optimal dose and method of administering BLF that may contribute to improvement in overall survival of LBW infants.
Methods:
Methods:
We will implement the study in two phases at the Aga Khan University Hospital. The first phase will be formative research, which we have completed. This phase mainly focused on a qualitative exploration of perceptions around feeding and caring practices of LBW newborns and a Trial of Improved Practices (TIPs) for the preparation and administration of BLF to the newborns. The second phase will be a three-arm double-blinded, individually randomized controlled trial. In this phase, we will randomly allocate two different daily oral prophylactic doses of BLF (150 mg or 300 mg) and placebo to 300 LBW neonates starting within the first 72 hours of birth continuing for the first 28 days of life.
Results:
Trial ongoing
Conclusions:
Trial ongoing Clinical Trial: Trial registration: ClinicalTrials.gov identifier: NCT03431558.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.